Savara (SVRA)
(Delayed Data from NSDQ)
$4.27 USD
+0.05 (1.18%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.28 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SVRA 4.27 +0.05(1.18%)
Will SVRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SVRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SVRA
Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks
3 Top Breakout Stocks to Add to Your Portfolio Now
SVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SVRA
Savara Announces New Employment Inducement Grant
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
Savara Breaks Above 200-Day Moving Average - Bullish for SVRA
Buy Rating Backed by Molbreevi’s Promising Trial Results and Market Potential for aPAP Treatment
Evercore ISI Reaffirms Their Buy Rating on Savara (SVRA)